Novoprotein Scientific Inc. (SHA:688137)
China
· Delayed Price · Currency is CNY 41.05
-1.14 (-2.70%)
At close: Mar 9, 2026
Novoprotein Scientific Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Operating Revenue | 151.51 | 127.4 | 153.05 | 264.33 | 341.79 | Upgrade
|
| Other Revenue | - | 0.15 | 0.14 | 0.22 | 0.11 | Upgrade
|
| Revenue | 151.51 | 127.56 | 153.19 | 264.55 | 341.9 | Upgrade
|
| Revenue Growth (YoY) | 18.78% | -16.73% | -42.09% | -22.62% | 90.11% | Upgrade
|
| Cost of Revenue | - | 73.47 | 70.69 | 54.3 | 54.55 | Upgrade
|
| Gross Profit | 151.51 | 54.08 | 82.5 | 210.25 | 287.35 | Upgrade
|
| Selling, General & Admin | - | 101.09 | 87.84 | 82.94 | 69.29 | Upgrade
|
| Research & Development | - | 49.92 | 44.79 | 41.1 | 34.1 | Upgrade
|
| Other Operating Expenses | 219.71 | 1.29 | 0.67 | 3.01 | 3.9 | Upgrade
|
| Operating Expenses | 219.71 | 154.39 | 131.72 | 128.27 | 111.17 | Upgrade
|
| Operating Income | -68.2 | -100.31 | -49.22 | 81.98 | 176.17 | Upgrade
|
| Interest Expense | - | -3.59 | -3.59 | -4.05 | -1.8 | Upgrade
|
| Interest & Investment Income | - | 41.48 | 49.42 | 9.07 | 2.39 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 0.71 | 0.65 | 2.84 | -0.81 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.52 | -0.43 | -0.49 | -0.16 | -0.18 | Upgrade
|
| EBT Excluding Unusual Items | -68.72 | -62.14 | -3.23 | 89.69 | 175.77 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | -1.8 | -1.75 | 3.55 | -0.14 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 0.05 | -0.09 | -0.04 | 0.03 | Upgrade
|
| Asset Writedown | - | -6.61 | - | - | -0.15 | Upgrade
|
| Other Unusual Items | - | 16.29 | 11.29 | 12.98 | 0.72 | Upgrade
|
| Pretax Income | -68.72 | -54.22 | 6.22 | 106.18 | 176.23 | Upgrade
|
| Income Tax Expense | 7.46 | 0.2 | -6.62 | 15.46 | 27.22 | Upgrade
|
| Net Income | -76.18 | -54.42 | 12.84 | 90.72 | 149.01 | Upgrade
|
| Net Income to Common | -76.18 | -54.42 | 12.84 | 90.72 | 149.01 | Upgrade
|
| Net Income Growth | - | - | -85.84% | -39.12% | 79.42% | Upgrade
|
| Shares Outstanding (Basic) | 70 | 70 | 71 | 57 | 40 | Upgrade
|
| Shares Outstanding (Diluted) | 70 | 70 | 71 | 57 | 40 | Upgrade
|
| Shares Change (YoY) | 0.18% | -2.23% | 25.05% | 42.83% | 151.52% | Upgrade
|
| EPS (Basic) | -1.09 | -0.78 | 0.18 | 1.59 | 3.73 | Upgrade
|
| EPS (Diluted) | -1.09 | -0.78 | 0.18 | 1.59 | 3.73 | Upgrade
|
| EPS Growth | - | - | -88.68% | -57.37% | -28.67% | Upgrade
|
| Free Cash Flow | - | -31.57 | 24.22 | -33.39 | 1.02 | Upgrade
|
| Free Cash Flow Per Share | - | -0.45 | 0.34 | -0.58 | 0.03 | Upgrade
|
| Dividend Per Share | - | - | 0.500 | 0.500 | - | Upgrade
|
| Gross Margin | 100.00% | 42.40% | 53.85% | 79.47% | 84.05% | Upgrade
|
| Operating Margin | -45.01% | -78.64% | -32.13% | 30.99% | 51.53% | Upgrade
|
| Profit Margin | -50.28% | -42.66% | 8.38% | 34.29% | 43.58% | Upgrade
|
| Free Cash Flow Margin | - | -24.75% | 15.81% | -12.62% | 0.30% | Upgrade
|
| EBITDA | -56.37 | -88.48 | -39.11 | 90.5 | 180.01 | Upgrade
|
| EBITDA Margin | -37.21% | -69.37% | -25.53% | 34.21% | 52.65% | Upgrade
|
| D&A For EBITDA | 11.83 | 11.83 | 10.11 | 8.52 | 3.83 | Upgrade
|
| EBIT | -68.2 | -100.31 | -49.22 | 81.98 | 176.17 | Upgrade
|
| EBIT Margin | -45.01% | -78.64% | -32.13% | 30.99% | 51.53% | Upgrade
|
| Effective Tax Rate | - | - | - | 14.56% | 15.45% | Upgrade
|
| Revenue as Reported | - | 127.56 | 153.19 | 264.55 | 341.9 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.